Non-alcoholic fatty liver (NAFLD) is the most common chronic liver disorder increasing morbidity and mortality worldwide with cardiovascular disease (CVD) being the main cause of death.¹ Recent findings from a meta-analysis of observational studies demonstrated an increased cardiovascular risk with NAFLD, especially with advanced fibrosis.² Therefore, with several studies highlighting this association, it may be important to consider cardiovascular screening in NAFLD patients in addition to the management of liver disease due to its potential in decreasing the disease burden.³

Weight control remains an indispensable component for the clinical management of type 2 diabetes mellitus (T2DM) in preventing cardiometabolic morbidity.1-3 People with T2DM who received weekly subcutaneous injection of semaglutide 2.4mg achieved superior and clinically meaningful reduction of body

Fatty liver encompasses broad spectrum of conditions that lead to accumulation of fat in the liver. In Asia, the prevalence of non-alcoholic fatty liver disease (NAFLD) and its subsets are increasing due to altered dietary habits and lifestyle factors.¹

Vitamin D deficiency has been reported in at least 1 billion people worldwide, while 50% of the population has vitamin D insufficiency.¹ Vitamin D deficiency arises from multiple causes including inadequate diet and insufficient exposure to sunlight.²

The increased prevalence of type 2 diabetes mellitus (T2DM) may cause an increase in chronic kidney disease burden.¹ Sodium-glucose cotransporter 2 (SGLT2) inhibitors are used to lower blood glucose levels in patients with T2DM,

Self-monitoring blood glucose (SMBG) is an integral part of self-management in patients with type 1 diabetes. However, the use of SMBG in patients with type 2 diabetes has caused some debates in the field.

Canagliflozin is the first sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes.1 Although canagliflozin offers benefits such as reductions in body weight, blood pressure, and risk for hypoglycemia,2 the US Food and Drug Administration (FDA) has included a